Compare PHAT & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | NIE |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 745.4M |
| IPO Year | 2019 | N/A |
| Metric | PHAT | NIE |
|---|---|---|
| Price | $9.62 | $26.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $19.83 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 64.8K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.04% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $4.25 | $22.74 |
| 52 Week High | $18.31 | $27.02 |
| Indicator | PHAT | NIE |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 65.39 |
| Support Level | N/A | $24.71 |
| Resistance Level | $12.83 | $27.02 |
| Average True Range (ATR) | 0.72 | 0.32 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 2.57 | 91.92 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.